ASCVD risk refinement with NT-proBNP for statin allocation among low- and intermediate risk individuals

Jelena Pavlović, Maryam Kavousi, M. Kamran Ikram, Daniel Bos, M. Arfan Ikram, Maarten J.G. Leening
doi: https://doi.org/10.1101/2024.04.09.24305587

ABSTRACT

Background Statin trials targeting low- to intermediate risk individuals, namely MEGA, JUPITER, and HOPE-3, have demonstrated benefit of statin use for primary prevention of atherosclerotic cardiovascular disease (ASCVD), but are poorly reflected in guideline recommendations for primary prevention of ASCVD. N-terminal pro-B-type natriuretic peptide (NT-proBNP) may refine ASCVD risk in low-to intermediate risk individuals eligible for HOPE-3, JUPITER and MEGA, and aid statin initiation in low- to intermediate risk populations.

Methods 5434 participants, aged 45 years and above from the prospective population-based Rotterdam Study, free of ASCVD, heart failure, and diabetes, were included between 1997 and 2008. Eligibility criteria for MEGA, JUPITER, and HOPE-3 trials were checked for each participant. ASCVD event rates, hazard ratios (HR), 5-year numbers needed to treat (NNT5y), and screen (NNS5y) per trial eligible population and NT-proBNP category (≤50, 50-100, and >100 pg/mL) were calculated.

Results Median age was 61.6 years, 58.9% were women, median NT-proBNP was 60 pg/mL. The proportions of participants eligible for MEGA, JUPITER and HOPE-3 were 34.9%, 10.4% and 23.7%. Incidence rates per 1000 person-years for ASCVD were 10.4 (95%CI: 60.1-67.9) for MEGA, 16.8 (95%CI: 13.6-20.6) for JUPITER, and 12.1 (95%CI: 10.3-14) for HOPE-3. Adjusted HR in trial eligible individuals for NT-proBNP >100 pg/mL compared to ≤50 pg/mL level were 1.73 (95%CI: 1.21-2.47), 1.46 (95%CI: 0.80-2.66) and 1.50 (95%CI: 0.99-2.26), respectively. Estimated NNT5y among trial eligible individuals with NT-proBNP levels >100 pg/mL based on high-intensity statin treatment, varied from 23 to 34 to prevent one ASCVD event, while NNS5y ranged between 56 and 134.

Conclusions NT-proBNP level >100 pg/mL identifies individuals at the highest ASCVD risk among low- to intermediate risk populations who are likely to benefit from statin treatment at acceptable NNT5y and NNS5y.

Clinical Perspective

  1. What is New?

    • NT-proBNP level >100 pg/mL can identify individuals at the highest ASCVD risk among low- to intermediate risk populations who are likely to benefit from statin treatment at acceptable numbers needed to treat and screen.

    • Among apparently healthy individuals without prior ASCVD and diabetes mellitus, 60% was deemed to be at low- to intermediate risk by qualifying for at least one of three RCT based on the trial eligibility criteria, and one out four individuals had NT-proBNP level >100 pg/mL.

  2. What are the Clinical Implications?

    • NT-proBNP level can be used for risk refining in low- to intermediate risk individuals who are most likely to benefit from statin initiation for ASCVD primary prevention.

INTRODUCTION

Management of blood cholesterol is one of the cornerstones of primary prevention of atherosclerotic cardiovascular disease (ASCVD).1,2 A variety of randomized clinical trials (RCT) have demonstrated the efficacy of statin treatment among individuals free of ASCVD.3,4 Three major RCT, namely the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA)5, Justification for the Use of Statins in Prevention: Intervention Trial Evaluating Rosuvastatin (JUPITER)6, and Heart Outcomes Prevention Evaluation-3 (HOPE-3)7,8, have established the benefit of statin treatment in low- to intermediate risk individuals free of ASCVD.

We previously demonstrated that the findings of these three trials were poorly reflected in the US and European cholesterol treatment guideline recommendations.9 In addition, extending statin treatment recommendations to healthy individuals at low ASCVD risk raised concerns of statin overprescription.10–12 Hence, the latest US and European guidelines suggest using additional non-traditional risk factors, referred to as either risk enhancers or risk modifiers, to refine, and thus improve risk assessment in individuals at low- or intermediate ASCVD risk.1,2

In this regard, N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a promising biomarker with potential to improve ASCVD risk assessment in low- to intermediate risk populations. NT-proBNP has been consistently associated with ASCVD risk,13,14 and is widely available and affordable,15 which makes it an appealing tool for ASCVD risk refinement in clinical practice. The value of NT-proBNP as a biomarker for risk refinement and statin allocation in primary prevention of ASCVD requires further evaluation.

In this study, we evaluate the application of NT-proBNP as a risk refining and decision-making tool in community-dwelling individuals meeting the eligibility criteria for three low- to intermediate risk statin RCT for primary prevention of ASCVD.

METHODS

Setting and Study Population

We used data from the Rotterdam Study, a prospective population-based cohort study drawn from the unselected population of a suburb in Rotterdam, designed to investigate etiology, preclinical phase, prognosis, and potential intervention targets for chronic diseases in mid- and late-life. The Rotterdam Study rationale and design have been described in detail previously.16

The Rotterdam Study recruited individuals in four subcohorts. Extensive examinations at baseline and follow-up visits were carried out every three to four years. NT-proBNP was measured in three subcohorts from 1997 to 2008. In total, 10,522 participants underwent examinations in these three visits combined, of which 9,326 participants had valid NT-proBNP measurement, informed consent, and follow-up (Figure S1).

All participants provided written informed consent to participate in the study and to have their information obtained from treating physicians. The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-PG). The Rotterdam Study has been entered into the Netherlands National Trial Register (NTR; www.trialregister.nl) and into the WHO International Clinical Trials Registry Platform (ICTRP; www.who.int/ictrp/network/primary/en/) under shared catalogue number NTR6831.

NT-proBNP Measurement

NT-proBNP was measured from blood samples stored at -80°C, collected in glass tubes with clot activator and serum separation gel. NT-proBNP was measured using an electrochemiluminescence immunoassay (Elecsys proBNP; Hoffman-La Roche Ltd., Basel, Switzerland) and Elecsys 2010 analyzer, as described previously.17,18

Assessment of ASCVD

The main outcome was incident ASCVD, composed of myocardial infarction, coronary revascularization, non-hemorrhagic stroke, and ASCVD mortality.19,20 Events were adjudicated until January 1st, 2015. Follow-up and adjudication of outcome events was based on the general practitioners’ and medical specialists’ reports and verified by the study physicians, in detail described previously.19,20

Assessment of Covariables

Information on medication use, smoking behavior, postmenopausal status, and medical history was collected by trained interviewers using a structured home interview. Anthropometric measures and laboratory testing were obtained during a visit to the research center.13 A detailed description of ASCVD risk factors assessment and used definitions for blood pressure, triglycerides, total, high-density and low-density cholesterol, glucose, c-reactive protein, thyroid-stimulating hormone, serum creatinine, estimated glomerular filtration rate, alanine aminotransferase, presence of diabetes mellitus and family history of premature coronary heart disease are provided in the Supplemental Methods.

Statin Trial Eligibility

We followed eligibility criteria for three double blind placebo-controlled RCT on statin use in primary prevention targeted at low- to intermediate risk individuals with hard ASCVD end points: MEGA,5,21 JUPITER,6 and HOPE-37 (Table 1, Table S1).

View this table:
Table 1. Overview of the clinical trial characteristics

Inclusion criteria among the RCT varied due to differences in design and hypothesis. Major RCT inclusion criteria included: age, sex, lipid levels, C-reactive protein levels, history of diabetes mellitus, blood pressure, and postmenopausal status for women (Table 1, Table S1). Data on a few minor exclusion criteria were not available in the Rotterdam Study, such as creatine phosphokinase levels, illicit drug abuse, and rare medical conditions (Table S1).

Finally, to select apparently healthy individuals and emulate eligibility criteria for three RCT (Figure S1), in the present analysis we included a total of 5434 participants over 45 years of age, without a history of diabetes mellitus, ASCVD, and heart failure, with low-density lipoprotein (LDL) cholesterol levels below 190 mg/dL (4.9 mmol/L), not using a statin, and without uncontrolled risk factors. The uncontrolled risk factors in essence reflected minor exclusion criteria defined by three RCT, such as uncontrolled hypertension, hypothyroidism, history of chronic liver disease, use of systemic corticosteroids or cyclosporin, and high levels of serum creatinine and triglycerides, as defined in the Supplemental Methods. History of ASCVD was defined as any of the following: myocardial infarction, coronary or other arterial revascularization procedure, stroke, transient ischemic attack, or repeated prescription of nitrates (as a proxy for angina pectoris).19,20,22,23 We excluded individuals with age-specific levels of NT-proBNP indicative of underlying heart failure (if age <50 years and NT-proBNP >450 pg/mL, or age 50-75 years and NT-proBNP >900 pg/mL, or age >75y and NT-proBNP >1800 pg/mL).24

Statistical Analysis

First, we determined the cardiovascular risk factor profiles for each trial, and proportions of the study population meeting eligibility criteria for MEGA, JUPITER, and HOPE-3. In addition, we divided the trial eligible populations using three NT-proBNP thresholds (≤50 pg/mL, 50-100 pg/mL, and >100 pg/mL).25

Next, we calculated incidence rates for ASCVD events per 1000 person-years in the entire study population, trial eligible subgroups, and by NT-proBNP categories.

To evaluate the risk refining properties of the three NT-proBNP categories, we applied Cox regression models. Specifically, we analyzed associations of continuous natural-log-transformed NT-proBNP, and NT-proBNP categories in relation to the incidence of ASCVD events in the total population as well as in trial eligible subgroups. The reference for comparison was the lowest NT-proBNP category (≤50 pg/mL). We report adjusted hazard ratios (HR) for two models: model 1, adjusted for age and sex, and model 2, additionally adjusted for traditional risk factors: current smoking, systolic blood pressure, total and high-density lipoprotein cholesterol.

To explore the potential yield of NT-proBNP as a risk refining and statin allocation tool in the context of ASCVD primary prevention, we calculated 5-year numbers needed to treat (NNT5y) and numbers needed to screen (NNS5y) for each NT-proBNP category.

Based on the observed ASCVD event rates and the anticipated risk reduction with statin therapy, we calculated NNT5y. We calculated NNT5y for 30% and 50% LDL cholesterol reduction, corresponding to treatment with moderate- and high-intensity statins, respectively.26 For primary prevention, expected relative risk reduction of 25% in major ASCVD events was used for each 38.7 mg/dL (1.0 mmol/L) of LDL cholesterol lowering.3 We calculated NNT5y using the following formula: NNT5y = 1 / (5 * [observed ASCVD incidence rate] * [observed median LDL in mmol/L] * [anticipated proportional LDL reduction] * [anticipated ASCVD relative risk reduction]).

NNS5y to prevent one ASCVD event were calculated based on the NNT5y and NT-proBNP level distributions for trial eligible subgroups. NNS5y were calculated by multiplying NNT5y with inverse probability of the prevalence of the NT-proBNP threshold, in total population and trial eligible subgroups.

Sensitivity analyses restricted to a composite coronary heart disease (CHD) outcome were performed and presented the corresponding results in the Supplemental Material. The CHD outcome was defined as a composite of myocardial infarction, coronary revascularization, and CHD mortality.19 For CHD, the relative risk reduction of 29% in CHD events was used for each 38.7 mg/dL (1.0 mmol/L) of LDL cholesterol lowering to calculate respective NNT5y and NNS5y.3

We had complete data for 95.7% of traditional cardiovascular risk factors. Missing values were handled by single imputation using an expectation-maximization algorithm, separately for each sex, using age and all other traditional risk factors.27 We used IBM SPSS Statistics version 25.0 (IBM Corp, Armonk, NY, USA) and R version 4.0.4 (R Foundation for Statistical Computing, Vienna, Austria) for all analyses.

RESULTS

Median age in the total population was 61.6 years and 58.9% were women. The median NT- proBNP was 60 pg/mL (Table 2). MEGA eligible individuals were younger and had lower median NT-proBNP levels compared to JUPITER and HOPE-3 eligible individuals. The HOPE-3 eligible population had the most unfavorable lipid profile.

View this table:
Table 2. Population characteristics

Overall, 1896 (34.9%, 95%CI: 33.6-36.2), 567 (10.4%, 95%CI: 9.6-11.3), and 1287 (23.7%, 95%CI: 22.6-24.8) individuals of the total study population fitted the eligibility criteria for MEGA, JUPITER, and HOPE-3, respectively (Figure 1). JUPITER had the highest proportion of eligible individuals with NT-proBNP levels >100 pg/mL (41.1%), as compared to MEGA (21.7%) and HOPE-3 (30.6%) eligible individuals (Table 2).

Figure 1.
Figure 1. General population eligibility for statin trials in primary prevention of ASCVD targeting low- and intermediate risk individuals

Abbreviations: ASCVD, atherosclerotic cardiovascular disease; HOPE-3, Heart Outcomes Prevention Evaluation-3; JUPITER, Justification for the Use of Statins in Prevention: Intervention Trial Evaluating Rosuvastatin; MEGA, The Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese.

In total population, during a mean (SD) follow-up of 9.9 (4.2) years, 681 first ASCVD events in total were observed, corresponding to an ASCVD event rate of 12.6 (95%CI: 11.7-13.6) per 1000 person-years. Among trial eligible individuals with NT-proBNP levels >100 pg/mL, JUPITER had the highest ASCVD incidence rate (24.0 per 1000 person-years), and MEGA the lowest (15.0 per 1000 person-years) (Table S2).

NT-proBNP >100 pg/mL was significantly associated with ASCVD incidence after adjusting for traditional risk factors (model 2) in the total study population and among individuals eligible for MEGA (Figures 2). Multivariable adjusted HR for ASCVD events comparing NT-proBNP levels of >100 pg/mL and ≤50 pg/mL were 1.56 (95%CI: 1.27-1.91; P<0.001) in the total population, 1.72 (95%CI: 1.20-2.45; P=0.003) among MEGA eligible, 1.46 (95%CI: 0.80-2.67; P=0.213) among JUPITER eligible, and 1.50 (95%CI: 1.00-2.27; P=0.052) among HOPE-3 eligible individuals (Figure 2). Adjustment for traditional risk factors only marginally affected the HR (Table S3). The ASCVD free survival was lowest across all trial eligible individuals when NT-proBNP levels were >100 pg/mL (Figure 3).

Figure 2.
Figure 2. Adjusted hazard ratios for incident ASCVD

* Natural-log-transformed NT-proBNP values.

Adjusted hazard ratios (model 2) for ASCVD with 95% confidence intervals per natural-log-transformed NT-proBNP values, comparing two NT-proBNP categories with NT-proBNP ≤50 pg/mL (reference group) in total population and per trial eligible subpopulations.

Abbreviations: ASCVD, atherosclerotic cardiovascular disease; HDL, high-density lipoprotein; HOPE-3, Heart Outcomes Prevention Evaluation-3; JUPITER, Justification for the Use of Statins in Prevention: Intervention Trial Evaluating Rosuvastatin; MEGA, The Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

Figure 3.
Figure 3. ASCVD free survival curves by NT-proBNP level and trial eligibility

Abbreviations: ASCVD, atherosclerotic cardiovascular disease; HOPE-3, Heart Outcomes Prevention Evaluation-3; JUPITER, Justification for the Use of Statins in Prevention: Intervention Trial Evaluating Rosuvastatin; MEGA, The Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

Estimated NNT5y to avoid one ASCVD event were lowest for JUPITER eligible individuals, except for those with NT-proBNP levels ≤50 pg/mL (Figure 4, Table S4). Among MEGA, JUPITER and HOPE-3 eligible with NT-proBNP levels >100 pg/mL, 48, 39 and 56 individuals would need to be treated with moderate-intensity statins for 5 years to prevent one ASCVD event. With high-intensity statins, NNT5y were 29 for MEGA, 23 for JUPITER, and 34 for HOPE-3.

Figure 4.
Figure 4. Numbers needed to treat and screen for five years to avoid a single ASCVD event with high-intensity statins

Panel A, Numbers needed to treat for five years to avoid a single ASCVD event with high-intensity statins, by NT-proBNP level. Panel B, Numbers needed to screen for five years to avoid a single ASCVD event with high-intensity statins, by NT-proBNP level.

Abbreviations: ASCVD, atherosclerotic cardiovascular disease; HOPE-3, Heart Outcomes Prevention Evaluation-3; JUPITER, Justification for the Use of Statins in Prevention: Intervention Trial Evaluating Rosuvastatin; MEGA, The Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

Among individuals with NT-proBNP levels >100 pg/mL for MEGA, JUPITER, and HOPE-3 eligible, NNS5y based on the NNT5y with high-intensity statins were 134, 56 and 111, respectively (Figure 4). Estimated NNT5y and NNS5y were lower for high-intensity statin treatment compared to moderate-intensity statin treatment (Table S4).

Results for CHD outcomes followed a similar pattern to those for ASCVD (Tables S5 and S6, Figures S2 and S3). Estimated NNT5y and NNS5y to prevent an ASCVD event were lower than those needed to prevent a CHD event (Table S4).

DISCUSSION

NT-proBNP levels >100 pg/mL identify individuals at an increased risk of ASCVD among individuals at low- to intermediate risk who are eligible for statin RCT for primary prevention of ASCVD.5–7 We found comparable numbers needed to treat to those reported by the three original trials. Our results imply that NT-proBNP could be considered as a risk refining tool among individuals at low- to intermediate risk for primary prevention of ASCVD.

The percentages of eligibility for three statin primary prevention trials were 34.9% for MEGA, 10.4% for JUPITER and 23.7% for HOPE-3, with minimal overlap between trials, meaning that these trials differentially selected low- to intermediate risk profiles in the general population free of ASCVD. Overall, 57.2% of the general population sample free of ASCVD and diabetes, was eligible for at least one of these three RCT, meaning that for these individuals, the evidence of the statin efficacy to prevent ASCVD is established. This finding emphasizes the broad evidence base for statin use in primary prevention of ASCVD, which is in stark contrast with the small number of selected very high-risk individuals that is currently strongly recommended statin therapy in the most recent European prevention guidelines.28 Although NT-proBNP >100 pg/mL was significantly associated with ASCVD incidence in the total study population and MEGA eligible individuals (Figures 2), but not among JUPITER and HOPE-3 eligible, the association was comparable across trial eligible populations. The lack of significant association might be explained with limited number of events during follow-up, given that substantially fewer individuals qualified for JUPITER and HOPE-3 compared to MEGA (Table S3).

In this study we used NT-proBNP as a tool to refine ASCVD risk to identify low- to intermediate risk individuals for whom evidence supports preventive statin treatment. To examine the yield of statin treatment in the trial eligible population we calculated NNT5y and NNS5y. NNT is commonly used in clinical trials to assess the acceptability of the investigated intervention.29,30 Generally, the lower the NNT, the more acceptable the intervention is. NNT over approximately five years of statin treatment reported by the three evaluated statin trials ranged from 25 to 119 (Table 1).5–8 In the present study, we report comparable NNT5y varying from 23 to 34 for ASCVD for high-intensity statins to prevent one event among trial eligible individuals with NT-proBNP levels >100 pg/mL. In addition, NNS provides an estimate of the number of individuals that need to undergo NT-proBNP testing to identify individuals at NT-proBNP levels >100 pg/mL, and subsequently prevent one ASCVD event in the coming five years. In our study, among trial eligible individuals, NNS5y ranged between 56 to 134 with high-intensity statins. Our results indicate that NT-proBNP level >100 pg/mL can identify individuals at the highest ASCVD risk among low- to intermediate risk populations who are likely to benefit from statin treatment at acceptable NNT5y and NNS5y. Ultimately, whether these estimated NNT5y and NNS5y are acceptable for clinical practice is highly dependent on the healthcare system. Although NNT has its limitations,30 it can inform a shared decision-making between patient and healthcare provider regarding the pros and cons of statin use in primary prevention of ASCVD.

Implications

As apparently healthy individuals at low- to intermediate ASCVD risk are more likely to have ASCVD risk around the decision thresholds, in this population NT-proBNP can further inform decision regarding the allocation of statin treatment. We demonstrated that statin initiation in this population based on NT-proBNP level of >100 pg/mL could be acceptable in terms of how many individuals would need to be screened and treated with statins to avoid one ASCVD event. Current US and European ASCVD prevention guidelines do not yet recommend the use of NT-proBNP as a risk enhancer or modifier for risk stratification.1,2 In contrast, NT- proBNP has been endorsed in the latest iteration of the ESC guidelines for peri-operative cardiac care to identify apparently healthy individuals at increased risk for peri-operative cardiac events.31 Furthermore, compared to imaging methods endorsed by the US and European ASCVD prevention guidelines, the price of a single NT-proBNP measurement is considerably lower. In addition, NT-proBNP testing could be easily integrated into routine clinical practice. Our results suggest that the application of NT-proBNP as a risk refining tool for primary prevention warrants further evaluation, including defining optimal age- and sex-specific thresholds for clinical decision-making in ASCVD risk refinement. For example, NT-proBNP levels are higher in women,32 NT-proBNP increases with age,24 and co-morbidities further affect levels of NT- proBNP.33

Limitations

Specific limitations of our study need to be addressed. As most of the Rotterdam Study population is of European descent (95.7% white), our findings require validation in other ethnicities. Although large differences across ethnicities are not expected, it is relevant to establish generalizability in different populations. Due to the healthy volunteer effect observed in the Rotterdam Study cohort, the prevalence of cardiovascular risk factors and ASCVD incidence rates during follow-up are likely somewhat lower than in real-world data setting.34 Therefore, our results need to be interpreted with caution when extrapolating findings to the broader population accessing healthcare services.

Conclusions

NT-proBNP levels >100 pg/mL identify individuals at the highest ASCVD risk among low- to intermediate risk populations who are likely to benefit from statin treatment at acceptable NNT5y and NNS5y. Almost 60% of the general population free of ASCVD and diabetes was eligible for at least one of three statin RCT, and one out four had NT-proBNP levels >100 pg/mL.

Data Availability

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

Sources of Funding

The Rotterdam Study is supported by the Erasmus MC and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research (NWO); the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly; the Netherlands Genomics Initiative; the Ministry of Education, Culture, and Science; the Ministry of Health, Welfare, and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. Dr Pavlović was supported by Erasmus Mundus Western Balkans, a project funded by the European Commission. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclosures

All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Leening reports receiving speaker fees from Sanofi; Daiichi Sankyo; and Novartis; and served on an advisory board for Boehringer Ingelheim. No other disclosures were reported.

Supplemental Material

Supplemental Methods

Tables S1-S6

Figures S1-S3

References 35-36

Non-standard Abbreviations and Acronyms

ASCVD
atherosclerotic cardiovascular disease
CHD
coronary heart disease
HOPE-3
Heart Outcomes Prevention Evaluation-3 Trial
JUPITER
Justification for the Use of Statins in Prevention: Intervention Trial Evaluating Rosuvastatin
MEGA
The Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese Trial
NNS
number needed to screen
NNT
number needed to treat
NT-proBNP
N-terminal pro-B-type natriuretic peptide
RCT
randomized controlled trial

Acknowledgments

The dedication, commitment, and contribution of inhabitants, general practitioners, and pharmacists to the Rotterdam Study are gratefully acknowledged.

References

  1. 1.↵
    Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:e285–e350.
    OpenUrlFREE Full Text
  2. 2.↵
    Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42:3227–3337. doi: 10.1093/eurheartj/ehab484
    OpenUrlCrossRefPubMed
  3. 3.↵
    Cholesterol Treatment Trialists’ (CTT) Collaborators. The Effects of Lowering LDL Cholesterol with Statin Therapy in People at Low Risk of Vascular Disease: Meta-analysis of Individual Data from 27 Randomised Trials. Lancet. 2012;380:581–590. doi: 10.1016/S0140-6736(12)60367-5
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155–1163. doi: 10.1016/s0140-6736(06)69472-5
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr. AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, Lopez-Jaramillo P, Leiter LA, Dans A, et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016;374:2021–2031. doi: 10.1056/NEJMoa1600176
    OpenUrlCrossRefPubMed
  8. 8.↵
    Bosch J, Lonn EM, Jung H, Zhu J, Liu L, Lopez-Jaramillo P, Pais P, Xavier D, Diaz R, Dagenais G, et al. Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. Eur Heart J. 2021;42:2995–3007. doi: 10.1093/eurheartj/ehab225
    OpenUrlCrossRef
  9. 9.↵
    Pavlović J, Greenland P, Deckers JW, Kavousi M, Hofman A, Ikram MA, Franco OH, Leening MJ. Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomised clinical trial evidence: The Rotterdam Study. Eur J Prev Cardiol. 2018;25:420–431. doi: 10.1177/2047487317743352
    OpenUrlCrossRef
  10. 10.↵
    Ioannidis JP. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines. JAMA. 2014;311:463–464.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.
    Abramson JD, Redberg RF. The opinion pages: Don’t give more patients statins. In: The New York Times. 2013:A33.
  12. 12.↵
    Navar AM. Questioning the Benefit of Statins for Low-Risk Populations—Medical Misinformation or Scientific Evidence?—Reply. JAMA Cardiology. 2019. doi: 10.1001/jamacardio.2019.5123
    OpenUrlCrossRef
  13. 13.↵
    Kavousi M, Elias-Smale S, Rutten JHW, Leening MJG, Vliegenthart R, Verwoert GC, Krestin GP, Oudkerk M, de Maat MPM, Leebeek FWG. Evaluation of Newer Risk Markers for Coronary Heart Disease Risk Classification: A Cohort Study. Ann Intern Med. 2012;156:438–444. doi: 10.7326/0003-4819-156-6-201203200-00006
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Lemos JAd, Ayers CR, Levine BD, deFilippi CR, Wang TJ, Hundley WG, Berry JD, Seliger SL, McGuire DK, Ouyang P, et al. Multimodality Strategy for Cardiovascular Risk Assessment. Circulation. 2017;135:2119–2132. doi: doi:10.1161/CIRCULATIONAHA.117.027272
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Ledwidge MT, O’Connell E, Gallagher J, Tilson L, James S, Voon V, Bermingham M, Tallon E, Watson C, O’Hanlon R. Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent’s Screening TO Prevent Heart Failure) study. Eur J Heart Failure. 2015;17:672–679.
    OpenUrl
  16. 16.↵
    Ikram MA, Kieboom BCT, Brouwer WP, Brusselle G, Chaker L, Ghanbari M, Goedegebure A, Ikram MK, Kavousi M, de Knegt RJ, et al. The Rotterdam Study. Design update and major findings between 2020 and 2024. Eur J Epidemiol. 2024.
  17. 17.↵
    Rutten JHW, Mattace-Raso FUS, Steyerberg EW, Lindemans J, Hofman A, Wieberdink RG, Breteler MMB, Witteman JCM, Meiracker AHvd. Amino-Terminal Pro-B-Type Natriuretic Peptide Improves Cardiovascular and Cerebrovascular Risk Prediction in the Population. Hypertension. 2010;55:785–791. doi: doi:10.1161/HYPERTENSIONAHA.109.143313
    OpenUrlCrossRef
  18. 18.↵
    Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, Sedor FA, Butch AW. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta. 2003;338:107–115. doi: 10.1016/j.cccn.2003.08.016
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    Leening MJG, Kavousi M, Heeringa J, van Rooij FJ, Verkroost-van Heemst J, Deckers JW, Mattace-Raso FU, Ziere G, Hofman A, Stricker BH, et al. Methods of Data Collection and Definitions of Cardiac Outcomes in the Rotterdam Study. Eur J Epidemiol. 2012;27:173–185.
    OpenUrlCrossRefPubMed
  20. 20.↵
    Berghout BP, Bos D, Koudstaal PJ, Ikram MA, Ikram MK. Risk of recurrent stroke in Rotterdam between 1990 and 2020: a population-based cohort study. Lancet Reg Health Eur. 2023;30:100651.
    OpenUrl
  21. 21.↵
    Nakamura H. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J. 2004;68:860–867.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    Bos MJ, van Rijn MJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Incidence and Prognosis of Transient Neurological Attacks. JAMA. 2007;298:2877–2885. doi: 10.1001/jama.298.24.2877
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    Maitland-van der Zee AH, Klungel OH, Stricker BHC, van der Kuip DA, Witteman JC, Hofman A, Leufkens HG, de Boer A. Repeated Nitrate Prescriptions as a Potential Marker for Angina Pectoris. A Comparison with Medical Information from the Rotterdam Study. Pharm World Sci. 2003;25:70–72. doi: 10.1023/a:1023292830670
    OpenUrlCrossRefPubMed
  24. 24.↵
    Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330–337. doi: 10.1093/eurheartj/ehi631
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    Ndumele CE, Matsushita K, Sang Y, Lazo M, Agarwal SK, Nambi V, Deswal A, Blumenthal RS, Ballantyne CM, Coresh J, et al. N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2016;133:631–638.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, et al. Interpretation of the Evidence for the Efficacy and Safety of Statin Therapy. Lancet. 2016;388:2532–2561. doi: 10.1016/S0140-6736(16)31357-5
    OpenUrlCrossRefPubMed
  27. 27.↵
    Dempster AP, Laird NM, Rubin DB. Maximum Likelihood From Incomplete Data via the EM Algorithm. Journal of the Royal Statistical Society Series B (Methodological). 1977;39:1–38. doi: 10.1111/j.2517-6161.1977.tb01600.x
    OpenUrlCrossRef
  28. 28.↵
    Mortensen MB, Tybjærg-Hansen A, Nordestgaard BG. Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines. JAMA Cardiol. 2022;7:836–843.
    OpenUrl
  29. 29.↵
    Elliott MH, Skydel JJ, Dhruva SS, Ross JS, Wallach JD. Characteristics and Reporting of Number Needed to Treat, Number Needed to Harm, and Absolute Risk Reduction in Controlled Clinical Trials, 2001-2019. JAMA Intern Med. 2021;181:282–284.
    OpenUrl
  30. 30.↵
    Saver JL, Lewis RJ. Number Needed to Treat: Conveying the Likelihood of a Therapeutic Effect. JAMA. 2019;321:798–799. doi: 10.1001/jama.2018.21971
    OpenUrlCrossRefPubMed
  31. 31.↵
    Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, De Hert S, de Laval I, Geisler T, Hinterbuchner L, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC). Eur Heart J. 2022;43:3826–3924. doi: 10.1093/eurheartj/ehac270
    OpenUrlCrossRefPubMed
  32. 32.↵
    Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976–982.
    OpenUrlFREE Full Text
  33. 33.↵
    Bernstein LH, Zions MY, Alam ME, Haq SA, Heitner JF, Zarich S, Seamonds B, Berger S. What is the best approximation of reference normal for NT-proBNP? Clinical levels for enhanced assessment of NT-proBNP (CLEAN). Journal of Medical Laboratory and Diagnosis. 2011;2:16–21.
    OpenUrl
  34. 34.↵
    Leening MJG, Heeringa J, Deckers JW, Franco OH, Hofman A, Witteman JC, Stricker BH. Healthy Volunteer Effect and Cardiovascular Risk. Epidemiology. 2014;25:470–471. doi: 10.1097/EDE.0000000000000091
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.
    Friedewald Levy R. I. FDS, William T. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
    OpenUrlAbstract/FREE Full Text
  36. 36.
    Expert Panel. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation and Trea. JAMA. 2001;285:2486–2497. doi: 10.1001/jama.285.19.2486
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.
    Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by r. Eur Heart J. 2007;28:2375–2414.
    OpenUrlCrossRefPubMedWeb of Science
Back to top
Posted April 12, 2024.
Download PDF
Data/Code
Email
ASCVD risk refinement with NT-proBNP for statin allocation among low- and intermediate risk individuals
Jelena Pavlović, Maryam Kavousi, M. Kamran Ikram, Daniel Bos, M. Arfan Ikram, Maarten J.G. Leening
medRxiv 2024.04.09.24305587; doi: https://doi.org/10.1101/2024.04.09.24305587
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area